GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2

The last two years have brought forward tremendous advances in the development of prophylactic and therapeutic approaches for the treatment of SARS-CoV-2 infections. Vaccines, monoclonal antibodies, antiviral agents, convalescent plasma, immunomodulators and other investigational therapies have either been approved or are at the investigational stage.

While serious outcomes of disease are no longer common, transmission remains high and the emergence of new variants capable of evading immunosurveillance induced by vaccination or escaping the neutralization capabilities of existing monoclonal antibodies. Thus, new medicines continue to be needed. Antibodies have been shown to be an effective treatment, and an intriguing approach is to use polyclonal (a mixture of different molecules) vs. monoclonal (a single molecule) antibodies. Indeed, the use of convalescent plasma was initiated to treat those most severely affected by infection, with the intent of delivering human polyclonal antibodies capable of neutralizing the virus.

Limitations thereof, however, are that convalescent plasma donated by vaccinated of previously infected individuals contain polyclonal antibodies against a few variants and are not effective against variants from the 8 SARS-CoV-2 clades thus far identified.   

Is it possible to create a ‘super’ mixture of antibodies reactive against all SARS-CoV-2 variants?  The answer is yes.  As described by Rena Mizrahi and her colleagues at GigaGgen, Inc., in South San Francisco, CA, it is now possible to produce such an antibody mixture using recombinant DNA technology. Titled “GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2” and published in the peer-reviewed journal Pathogens, this report by Dr. Mizrahi and her team makes for an interesting read into the development of recombinant oligoclonal antibodies against SARS-CoV-2. In addition to her colleagues at GigaGgen and collaborating institutions, Dr. Mizrahi’s team includes the following members of our team: 

  • Steven Chamow, Senior Vice President, CMC 
  • Wendy Lin, Consultant 
  • Charles Olsen, Consultant 
Publications
Published on:
August 2, 2022
Written by:
Steven Chamow, Wendy Lin, Charles Olsen
About Alira Health

As experienced CMC consultants, we can help you navigate the complex demands of product development and manufacture. We can provide your company with strategic advice and solutions designed to ensure success across the full product lifecycle.

Related news

Events February 2, 2023
ACDM 2023
We are pleased to announce that we will be sponsoring and attending ACDM 2023. ACDM23 offers a full two-day program of expert speakers, specialist panels, workshops and debates which(...)
Clinical Data Science
Blog December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Blog December 14, 2022
How to Optimize Clinical Research with Patient Advisory Boards
Patient engagement is increasingly essential to all stages of product development—particularly clinical research.
Clinical Patient Advocacy Patient Centric
Events November 30, 2022
Innovations in Wound Healing
We are excited to attend and sponsor a poster presentation at the Innovations in Wound Healing event this year. This unique meeting is led by a group of experienced educators, scientists(...)
Clinical Patient Centric Wound Healing
Publications September 16, 2022
Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
The rise of technology in clinical research allows us to capture meaningful aspects of health in clinical study participants.
Biometrics Clinical eCOA
Blog September 7, 2022
The Promise and Reality of Decentralized and Hybrid Clinical Trials in Europe Today
To understand the challenges related to hybrid and decentralized trials and ways to overcome them, we spoke with Dr. Hervé Solatges, Product Management, Evidence, and Innovation (DCT(...)
Clinical Decentralized Clinical Trials Hybrid Clinical Trials
Blog September 5, 2022
Taking In-Licensed Biologics to Market: Challenges, Complexities, and Ways to Overcome Them
Taking a biologic through drug development to market is highly complex and filled with challenges. To understand these challenges, their implications and how to overcome them, we spoke(...)
Biologics Clinical Drug Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.